A Case of Severe Peripheral Polyneuropathy Occurring after Entecavir Treatment in a Hepatitis B Patient.
10.4166/kjg.2016.67.4.216
- Author:
Ji Hyun SONG
1
;
Si Yeon KIM
;
Jae Kyoung SHIN
;
So Dam HONG
;
Kyu Sung RIM
;
Ha Na PARK
;
Joo Ho LEE
;
Yun Bin LEE
;
Seung Hun OH
;
Seong Gyu HWANG
Author Information
1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea. sghwang@cha.ac.kr
- Publication Type:Case Reports
- Keywords:
Entecavir;
Polyneuropathies;
Hepatitis B
- MeSH:
Administration, Oral;
Antiviral Agents/*adverse effects/therapeutic use;
Brain/diagnostic imaging;
Drug Therapy, Combination;
Duloxetine Hydrochloride/therapeutic use;
Glucocorticoids/therapeutic use;
Guanine/adverse effects/*analogs & derivatives/therapeutic use;
Hepatitis B, Chronic/drug therapy;
Humans;
Male;
Middle Aged;
Polyneuropathies/*diagnosis/drug therapy/etiology;
Prednisolone/therapeutic use;
Pregabalin/therapeutic use;
Tomography, X-Ray Computed
- From:The Korean Journal of Gastroenterology
2016;67(4):216-219
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Entecavir (Baraclude®) is an oral antiviral drug used for the treatment of HBV. Entecavir is a reverse transcriptase inhibitor which prevents the HBV from multiplying. Most common adverse reactions caused by entecavir are headache, fatigue, dizziness, and nausea. Until now, there has been no report of peripheral neuropathy as a side effect associated with entecavir treatment. Herein, we report a case of peripheral neuropathy which probably occurred after treatment with entecavir in a hepatitis B patient. The possibility of the occurrence of this side effect should be carefully taken into consideration when a patient takes a high dose of entecavir for a long period of time or has risk factors for neuropathy at the time of initiating entecavir therapy.
